Overview

Treatment of Transfusion-dependent Nonsevere Aplastic Anemia With Luspatercept: a Multicenter Prospective Clinical Study

Status:
NOT_YET_RECRUITING
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn whether Luspatercept alone or in combination with Deferasirox can promote hematopoietic function in patients with transfusion-dependent non-severe aplastic anemia, as well as to assess the safety and efficacy of this treatment approach. The main questions it aims to answer is: whether the combination therapy of Luspatercept and Deferasirox can improve hemoglobin levels in these patients. Participants will receive Luspatercept every 3 to 5 weeks based on hemoglobin response, undergo complete blood counts every 1 to 3 weeks, and receive other necessary evaluations as required.
Phase:
NA
Details
Lead Sponsor:
The First Affiliated Hospital of Zhejiang Chinese Medical University
Treatments:
Deferasirox
luspatercept